
A study examines the role of PSMA-PET in biopsy-free radical prostatectomy for clinically significant prostate cancer. The study reveals a 30% false-positive rate for PSMA-PET in detecting prostate cancer, highlighting concerns about benign prostatic hyperplasia (BPH)-related inaccuracies. Maximum standardized uptake value (SUVmax) proves crucial, effectively excluding BPH and Grade Group 1 patients. Specific criteria, such as a stringent PET score and Prostate Imaging Reporting and Data System, demonstrate promising sensitivity and specificity in diagnosing significant prostate cancer.
Like
Save
Share